13D Filings
ARS Pharmaceuticals, Inc.
SPRY
Amendment
Ownership

10.72%

Total Shares

10,514,657

Issuer CIK

1671858

CUSIP

82835W108

Event Date

Mar 19, 2025

Accepted

Mar 24, 2025, 07:57 PM

Reporting Persons (6)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
Deerfield Management Company, L.P.
Partnership
10.72%10,514,657010,514,657
James E. Flynn
Individual
10.72%10,514,657010,514,657
Deerfield Mgmt III, L.P.
Partnership
5.36%5,257,32905,257,329
Deerfield Private Design Fund III, L.P.
Partnership
5.36%5,257,32905,257,329
Deerfield Mgmt IV, L.P.
Partnership
5.36%5,257,32805,257,328
Deerfield Private Design Fund IV, L.P.
Partnership
5.36%5,257,32805,257,328
Disclosure Items (2)

Security Title

Common Stock, par value $0.0001 per share

Issuer Name

ARS Pharmaceuticals, Inc.

Percentage of Class

(1) Deerfield Mgmt III Number of shares: 5,257,329 (comprised of shares held by Deerfield Private Design Fund III) Percentage of shares: 5.36% (2) Deerfield Private Design Fund III Number of shares: 5,257,329 Percentage of shares: 5.36% (3) Deerfield Mgmt IV Number of shares: 5,257,328 (comprised of shares held by Deerfield Private Design Fund IV) Percentage of shares: 5.36% (4) Deerfield Private Design Fund IV Number of shares: 5,257,328 Percentage of shares: 5.36% (5) Deerfield Management Number of shares: 10,514,657 (comprised of shares held by Deerfield Private Design Fund III and Deerfield Private Design Fund IV) Percentage of shares: 10.72% (6) Flynn Number of shares: 10,514,657 (comprised of shares held by Deerfield Private Design Fund III and Deerfield Private Design Fund IV) Percentage of shares: 10.72%

Number of Shares

(1) Deerfield Mgmt III Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 5,257,329 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 5,257,329 (2) Deerfield Private Design Fund III Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 5,257,329 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 5,257,329 (3) Deerfield Mgmt IV Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 5,257,328 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 5,257,328 (4) Deerfield Private Design Fund IV Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 5,257,328 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 5,257,328 (5) Deerfield Management Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 10,514,657 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 10,514,657 (6) Flynn Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 10,514,657 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 10,514,657 Flynn is the managing member of the general partner of each of Deerfield Mgmt IV, Deerfield Mgmt III and Deerfield Management. Deerfield Mgmt III is the general partner of Deerfield Private Design Fund III and Deerfield Mgmt IV is the general partner of Deerfield Private Design Fund IV. Deerfield Management is the investment manager of the Deerfield Funds. *Percentage beneficial ownership reported herein reflects 98,119,804 shares of Common Stock outstanding as of March 17, 2025, as reported by the Company in its Annual Report on Form 10-K for the year ended December 31, 2024.